Skip to content

Polysomnographic Findings in Nasal Polyposis

Effects of Endoscopic Sinus Surgery on Sleep Disorder in Patients With Chronic Rhinosinusitis With Polyps

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03725956
Acronym
POLYSOMNO
Enrollment
30
Registered
2018-10-31
Start date
2019-01-17
Completion date
2026-12-01
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis With Nasal Polyps, Obstructive Sleep Apnea

Keywords

Nasal polyposis, sleep, sinus surgery, polysomnography, quality of life

Brief summary

Nasal polyposis (NP) is a chronic inflammatory disease of the nasal and sinus mucosa leading to protrusion of edematous polyps in the nasal cavity. Prevalence of NP among the chronic rhinosinusitis patients is 25-30 %. NP leads to significant limitations in physical, emotional and social aspects of life of the affected patients. Sleep disorder is frequently reported by those patients with impaired nasal breathing. Till now few studies have objectively assessed the impact of NP on sleep quality. the objectives are to figure out sleep disturbances in NP and to analyze the outcomes of sinus surgery on sleep recovering.

Detailed description

the objectives are to figure out sleep disturbances in NP and to analyze the outcomes of sinus surgery on sleep recovering.

Interventions

PROCEDUREEndoscopic sinus surgery

Surgical procedure under general anaesthesia: Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who underwent endoscopic sinus surgery for recalcitrant nasal polyposis (failure of a 4-month corticosteroid medical treatment) Social insured patient * Patient willing to comply with all procedures of the study and its duration * Patient giving consent

Exclusion criteria

* Patients with previous nasal surgery for nasal polyposis * Patients with previous continuous positive airway pressure therapy for obstructive sleep apnea * Non-coverage by the social security scheme * Patient unable to receive informed information * Refusal to sign the consent * Person deprived of the liberty * Person benefiting from a system of legal protection (guardianship…)

Design outcomes

Primary

MeasureTime frameDescription
Change in Slow-wave sleep duration1 month before surgery and 3 months postoperativelySlow-wave sleep duration is measured one month before surgery and 3 months after surgery

Secondary

MeasureTime frameDescription
change in total sleep durationAt 1 month before surgery and at 3 months postoperativelyduration in min of total sleep at each endpoint
Change in the number of brief wakefulnessAt 1 month before surgery and at 3 months postoperativelycomparison of the number of wakefulness between visits
change in Apnea-hypopnea indexAt 1 month before surgery and at 3 months postoperativelyThis index measures the number of apnea and hypopnea during the total sleep duration.
Change in time with oxygen desaturation below 90%At 1 month before surgery and at 3 months postoperativelydesaturation before anf after surgery measured
change in Epworth sleepiness scale scoresAt 1 month before surgery and at 3 months postoperativelyThe Epworth sleepiness scale score is a questionnaire based of 8 questions assessing daytime sleepiness. Each question is graded from 0 to 3. A total score ranging from 0 to 24 is established: 1 to 6 points: Normal sleep 7 to 8 points: Average sleepiness 9 to 24 points: Abnormal (possibly pathologic) sleepiness

Countries

France

Contacts

CONTACTGeoffrey Mortuaire, MD
geoffrey.mortuaire@chru-lille.fr03 20 44 56 72
PRINCIPAL_INVESTIGATORGeoffrey Mortuaire, MD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026